سعر الفيسكو 80 مكجم/ استنشاق 2022

Alvesco 80 is a pressurised metered-dose inhaler delivering ciclesonide 80 micrograms per actuation, an inhaled corticosteroid prodrug for maintenance control of persistent asthma; listed in Egypt under Nycomed.

• Treatment to control persistent asthmaPopulation: Adults and adolescents 12 years and older (UK SmPC)electronic medicines compendium (emc), UK
• Maintenance treatment of asthma as prophylactic therapy (not for relief of acute bronchospasm)Population: Adults and paediatric patients 12 years and older (US label)DailyMed (U.S. National Library of Medicine)

• Uncommon: paradoxical bronchospasm, dysphonia, cough after inhalation, application-site reactions and dryness, oral fungal infections, headache, nausea, vomiting, bad taste, palpitations, eczema and rash. Rare: angioedema, hypersensitivity, hypertension. Frequency not known: blurred vision.International label, same product · electronic medicines compendium (emc), UK

• Hypersensitivity to ciclesonide or any of the excipients.International label, same product · electronic medicines compendium (emc), UK
• Primary treatment of status asthmaticus or other acute asthma episodes requiring intensive measures.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Not for relief of acute asthma or status asthmaticus; use with caution in active or quiescent pulmonary tuberculosis and fungal, viral or bacterial infections.International label, same product · electronic medicines compendium (emc), UK
• Systemic corticosteroid effects may occur, especially at high doses for long periods: adrenal suppression, growth retardation in children and adolescents (monitor height), decreased bone mineral density, cataract, glaucoma and psychological or behavioural effects; visual disturbance may indicate central serous chorioretinopathy.International label, same product · electronic medicines compendium (emc), UK
• Paradoxical bronchospasm with an immediate increase in wheezing may occur; stop treatment and use a short-acting bronchodilator.International label, same product · electronic medicines compendium (emc), UK

• Potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir, nelfinavir, cobicistat-containing products)Increase exposure to the active metabolite des-ciclesonide (about 3.5-fold with oral ketoconazole); avoid unless the benefit outweighs the risk of systemic corticosteroid effects.electronic medicines compendium (emc), UK

• Use in pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus, at the lowest effective dose; infants exposed in utero should be observed for hypoadrenalism.International label, same product · electronic medicines compendium (emc), UK
• No adequate human data; low systemic exposure after inhalation; corticosteroid-type teratogenicity seen in rabbits given subcutaneous ciclesonide, none in rats given oral doses up to 15 times the maximum recommended human inhaled dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Use during breastfeeding only if the expected benefit to the mother outweighs any possible risk to the infant.International label, same product · electronic medicines compendium (emc), UK

• Ciclesonide: Prodrug with low glucocorticoid-receptor affinity that is converted by esterases in the lung to the active metabolite desisobutyryl-ciclesonide (C21-des-methylpropionyl-ciclesonide), which has pronounced anti-inflammatory activity.